Vortioxetine for Cancer Patients With Depression: An Observational Study

Cancer Clinical Trial

Official title:

Vortioxetine for Cancer Patients With Depression: An Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04253678
• Other study ID #: VOR001
• Status: Recruiting
• Start date: December 12, 2019
• Est. completion date: July 2020

Study information

• Verified date: January 2020
• Source: University of Malaya
• Contact: Chong Guan Ng
• Phone: 012 3408 813
• Email: chong_guan[@]um.edu.my
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational antidepressant study is to determine the efficacy of vortioxetine on depression and cognitive function, and elucidate its potential effects on quality of life in patients with cancer (of any origin). We hypothesise that given its unique mechanism of action as a multimodal serotonin modulator, vortioxetine is set to achieve the above goals while maintaining a favourable side effect profile.

Description:

Cancer is always a feared illness and the diagnosis of cancer has huge psychological impact on the patients. Depression is one of the most common psychiatric sequelae and affects the disease outcome in cancer patients. Along with depression, cancer patients are also vulnerable to develop cognitive impairment. It could be related to the cancer or its treatment. Cognitive impairment that occurs among cancer patient is known as cancer related cognitive impairment (CRCI). Depression together with cognitive impairment adversely affect the quality of life of cancer patients. To date, the optimal treatment of depression in cancer is not established. The number of studies investigated the efficacy of pharmacotherapy for depression in cancer patient is limited. The evidence of treatment for cognitive impairment in depressed cancer patients is even more scarce.

Vortioxetine is one of the latest marketed antidepressants in Malaysia. It has numerous additional effects as compared to other conventional antidepressants. In addition to blockade of the serotonin transporter (SERT), vortioxetine has affinity for 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors and as such, it is described as a 'multimodal serotonin modulator'. This may explain the additional benefit of vortioxetine in the treatment of depression as compared to other antidepressants. Furthermore, the unique mechanism of action of vortioxetine was also reported to improve cognitive function in patients with depression.

General Objective:

To examine the effect of vortioxetine in improving the depressive symptoms, cognitive impairment and quality of life in cancer patients who have major depressive disorder.

Specific Objectives:

1. To determine whether treatment with antidepressant vortioxetine is effective to improve depressive symptoms in patients diagnosed with cancer (of any origin) and major depressive disorder.

2. To determine whether treatment with antidepressant vortioxetine is effective to improve cognitive impairment in patients diagnosed with cancer (of any origin) and major depressive disorder.

3. To determine whether treatment with antidepressant vortioxetine is effective to improve quality of life in patients diagnosed with cancer (of any origin) and major depressive disorder.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 140
• Est. completion date: July 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged between 18 and 65 years old

• Literate and able to understand English or Malay

• Diagnosed with Major Depressive Disorder

• Diagnosed with cancer of any origin

Exclusion Criteria:

• Medically unstable

• Delirium

• Actively psychotic

• Cognitive deficits of other causes

• Primary or secondary cerebral/cranial tumors

Related Conditions & MeSH terms

• Cancer
• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Vortioxetine
Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion

Locations

Country	Name	City	State
Malaysia	Hospital Raja Permaisuri Bainun, Ipoh	Ipoh	Perak
Malaysia	Hospital Tengku Ampuan Rahimah Klang	Klang	Selangor
Malaysia	Hospital Kuala Lumpur	Kuala Lumpur
Malaysia	Hospital Putrajaya	Kuala Lumpur
Malaysia	National Cancer Institute	Kuala Lumpur
Malaysia	Pusat Perubatan Universiti Kebangsaan Malaysia	Kuala Lumpur
Malaysia	University Malaya Medical Centre	Kuala Lumpur
Malaysia	Hospital Sungai Buloh	Sungai Buloh	Selangor

Sponsors (1)

Lead Sponsor	Collaborator
University of Malaya

Country where clinical trial is conducted

Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Montgomery-Asberg Depression Rating Scale (MADRS)	The MADRS is a widely used clinical rating scale for depression. It consists of 10 items evaluating core symptoms of depression (Montgomery & Äsberg, 1979; Montgomery et al., 1978). Nine of the items are based upon patient report, and one is on the rater's observation during the rating interview. MADRS items are rated on a 0-6 continuum (0=no abnormality, 6=severe). The MADRS is relatively quick to administer and addresses core mood symptoms of depression such as sadness, tension, lassitude, pessimistic thoughts, and suicidal thoughts.	baseline (week 1), week 2, week 4, week 8, week 12
Primary	Changes in Perceived Deficits Questionnaire - 5 items (PDQ-5)	The PDQ-5 is a brief patient-rated scale to assess subjective cognitive dysfunction in people with depression. The PDQ originally is a 20-item questionnaire developed by Dr. Michael Sullivan at McGill University as a scale for use in patients with multiple sclerosis that generates a total score and 4 subscale scores (attention/concentration, retrospective memory, prospective memory, and planning/organization) (Sullivan et al., 1990). A 5-item version (PDQ-D-5) is a brief version and has been adapted and validated for use in patients with major depressive disorder.	baseline (week 1), week 2, week 4, week 8, week 12
Secondary	Changes in Clinical Global Impression (CGI)	The CGI allows psychiatrist to assess the patient's condition relative to baseline and rate the change on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).	baseline (week 1), week 2, week 4, week 8, week 12
Secondary	Changes in EORTC-QLQ-C30	The EORTC QLQ-C30 is widely used clinical scale for measurement of cancer-specific quality of life. It contains five functioning scales (physical, social, role, cognitive, and emotional functioning), eight symptom scales (fatigue, nausea/vomiting, pain, dyspnea, sleep disturbances, appetite loss, constipation, and diarrhea), financial impact, and overall quality of life. All scale scores are linearly converted to range from 0 to 100. For the functioning scales and global QOL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden (Aaronson et al., 1993).	baseline (week 1), week 2, week 4, week 8, week 12